Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MRVI NASDAQ:ORIC NASDAQ:PHAT NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRVIMaravai LifeSciences$4.29-1.8%$3.44$1.95▼$4.99$1.12B0.622.59 million shs2.05 million shsORICOric Pharmaceuticals$8.34-3.0%$10.61$4.53▼$14.93$890.25M1.111.34 million shs2.74 million shsPHATPhathom Pharmaceuticals$13.05+3.9%$11.61$3.10▼$18.31$1.00B0.571.45 million shs1.67 million shsSGMTSagimet Biosciences$7.37-3.0%$6.01$3.08▼$11.41$247.65M3.63.48 million shs684,170 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRVIMaravai LifeSciences-1.83%+8.88%+30.79%+44.93%+116.67%ORICOric Pharmaceuticals-3.02%-5.33%-20.80%-16.52%+71.60%PHATPhathom Pharmaceuticals+3.90%+6.70%+3.00%+8.57%+301.54%SGMTSagimet Biosciences-3.03%-3.53%+33.03%+45.65%+137.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRVIMaravai LifeSciences$4.29-1.8%$3.44$1.95▼$4.99$1.12B0.622.59 million shs2.05 million shsORICOric Pharmaceuticals$8.34-3.0%$10.61$4.53▼$14.93$890.25M1.111.34 million shs2.74 million shsPHATPhathom Pharmaceuticals$13.05+3.9%$11.61$3.10▼$18.31$1.00B0.571.45 million shs1.67 million shsSGMTSagimet Biosciences$7.37-3.0%$6.01$3.08▼$11.41$247.65M3.63.48 million shs684,170 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRVIMaravai LifeSciences-1.83%+8.88%+30.79%+44.93%+116.67%ORICOric Pharmaceuticals-3.02%-5.33%-20.80%-16.52%+71.60%PHATPhathom Pharmaceuticals+3.90%+6.70%+3.00%+8.57%+301.54%SGMTSagimet Biosciences-3.03%-3.53%+33.03%+45.65%+137.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRVIMaravai LifeSciences 2.50Moderate Buy$5.5028.21% UpsideORICOric Pharmaceuticals 2.71Moderate Buy$19.80137.41% UpsidePHATPhathom Pharmaceuticals 2.88Moderate Buy$25.0091.57% UpsideSGMTSagimet Biosciences 2.67Moderate Buy$28.63288.40% UpsideCurrent Analyst Ratings BreakdownLatest SGMT, PHAT, MRVI, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026MRVIMaravai LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026MRVIMaravai LifeSciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.005/8/2026MRVIMaravai LifeSciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.50 ➝ $5.505/5/2026ORICOric Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $16.005/4/2026SGMTSagimet Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $49.005/1/2026SGMTSagimet Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026SGMTSagimet Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $25.004/21/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SGMTSagimet Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRVIMaravai LifeSciences$185.74M5.94$0.41 per share10.44$1.44 per share2.98ORICOric PharmaceuticalsN/AN/AN/AN/A$4.01 per shareN/APHATPhathom Pharmaceuticals$175.11M5.94N/AN/A($4.22) per share-3.09SGMTSagimet Biosciences$2M120.06N/AN/A$3.14 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRVIMaravai LifeSciences-$130.77M-$0.71N/AN/AN/A-51.07%-17.87%-9.08%N/AORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%N/APHATPhathom Pharmaceuticals-$221.25M-$2.12N/A8.37N/A-76.77%N/A-44.29%N/ASGMTSagimet Biosciences-$51.04M-$1.34N/AN/AN/AN/A-37.57%-35.52%N/ALatest SGMT, PHAT, MRVI, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SGMTSagimet Biosciences-$0.39-$0.33+$0.06-$0.33N/AN/A5/7/2026Q1 2026MRVIMaravai LifeSciences-$0.05$0.01+$0.06-$0.02$53.00 million$65.84 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A3/11/2026Q4 2025SGMTSagimet Biosciences-$0.43-$0.29+$0.14-$0.29N/AN/A2/26/2026Q4 2025PHATPhathom Pharmaceuticals-$0.09-$0.08+$0.01-$0.29$57.44 million$57.58 million2/25/2026Q4 2025MRVIMaravai LifeSciences-$0.07-$0.04+$0.03-$0.24$49.06 million$49.87 million2/23/2026Q4 2025ORICOric Pharmaceuticals-$0.34-$0.30+$0.04-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMRVIMaravai LifeSciencesN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRVIMaravai LifeSciences0.725.915.69ORICOric PharmaceuticalsN/A16.3316.33PHATPhathom PharmaceuticalsN/A2.212.16SGMTSagimet BiosciencesN/A20.3322.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRVIMaravai LifeSciences50.25%ORICOric Pharmaceuticals95.05%PHATPhathom Pharmaceuticals99.01%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipMRVIMaravai LifeSciences2.49%ORICOric Pharmaceuticals5.70%PHATPhathom Pharmaceuticals9.33%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRVIMaravai LifeSciences610257.07 million250.67 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableSGMTSagimet Biosciences832.58 million27.80 millionOptionableSGMT, PHAT, MRVI, and ORIC HeadlinesRecent News About These CompaniesSagimet Biosciences: Making The Bull Case For Differentiated DenifanstatMay 14 at 3:01 PM | seekingalpha.comSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13 at 7:00 AM | globenewswire.comSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12 at 7:30 AM | globenewswire.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from JonesTradingMay 11, 2026 | theglobeandmail.comSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in ChicagoMay 11, 2026 | globenewswire.comSagimet Biosciences (SGMT) Expected to Announce Earnings on ThursdayMay 7, 2026 | marketbeat.comSagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?May 5, 2026 | zacks.comDoes Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?May 5, 2026 | zacks.comHC Wainwright Issues Optimistic Estimate for SGMT EarningsMay 5, 2026 | marketbeat.comCanaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00May 4, 2026 | marketbeat.comSagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M RaiseApril 30, 2026 | marketbeat.comGuggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00April 29, 2026 | marketbeat.comSagimet Biosciences stock surges 30% on acne trial plansApril 28, 2026 | au.investing.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 40.04%April 28, 2026 | aaii.comASagimet Biosciences Shares Jump 30% on Acne Trial Expansion PlansApril 28, 2026 | finance.yahoo.comWhy Is Sagimet Biosciences Stock Trading Higher On Monday?April 27, 2026 | benzinga.comSagimet Updates Investor Presentation After Key Clinical MilestonesApril 27, 2026 | tipranks.comSagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 MillionApril 27, 2026 | quiverquant.comQSagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockApril 27, 2026 | globenewswire.comSagimet Biosciences Provides Strategic and Corporate UpdatesApril 27, 2026 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 27, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSGMT, PHAT, MRVI, and ORIC Company DescriptionsMaravai LifeSciences NASDAQ:MRVI$4.29 -0.08 (-1.83%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$4.32 +0.04 (+0.82%) As of 05/14/2026 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Oric Pharmaceuticals NASDAQ:ORIC$8.34 -0.26 (-3.02%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$8.36 +0.03 (+0.30%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Phathom Pharmaceuticals NASDAQ:PHAT$13.05 +0.49 (+3.90%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$13.05 0.00 (0.00%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Sagimet Biosciences NASDAQ:SGMT$7.37 -0.23 (-3.03%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$7.11 -0.26 (-3.51%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
